Sustained white cell cytokine activation in idiopathic dilated cardiomyopathy despite haemodynamic improvement with medical therapy

Cardiovascular Journal of South Africa

Volumn 16, Issue 4, 2005, Pages 200-204

  Brooksbank, Richard ^a   Woodiwiss, Angela ^a   Sliwa, Karen ^a   Deftereos, Dawn ^a   Essop, Mohammed R ^a   Sareli, Pinhas ^a   Norton, Gavin R ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOKINE; ENDOTOXIN; LOSARTAN; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EDEMA; ENZYME ACTIVATION; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART PERFUSION; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE ACTIVATION; MALE; TUMOR CELL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOMYOPATHY, DILATED; CYTOKINES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LEUKOCYTES; LOSARTAN; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 28244468626     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Levine B, Kalman J, Mayer L, Fiuit HM, Packer M. Elevated circulating levels of tumor necrosis factor alpha in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
2. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-566.
3. Torre-Amione G, Capaslera S, Benedict C, Oral Y, Young JB, Mann DL. Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-1206.
4. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 2: 243-249.
5. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of pro-inflammatory cytokines. Chest 1994; 105: 897-904.
6. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95: 778-781.
7. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711.
8. Doyama K, Fujiwara H, Fukimoto M, et al. Tumor necrosis factor is expressed in the cardiac tissues of patients with heart failure. Int J Cardiol 1996; 31: 391-398.
9. Keith M, Geranmayegan A, Sole MJ. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-1356.
10. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347: 1151-1155.
11. Patrianakos AP, Parthenakis FI, Papadimitriou EA, Diakakis GF, Tzerakis PG, Nikitovic D, Vardas PE. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. Eur J Heart Fail 2004; 6: 735-743.
12. Mann DL. Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 1999; 353: 1812-1813.
13. Torre-Amione G, Kapadia S, Lee J, Bier RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487-1493.
14. Anker SD, Egerer KR, Volle HD, Koi WJ, Poole-Wilson PA, Coats AJS. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1999; 79: 1426-1429.
15. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-1842.
16. Genth-Zotz S, von Haehling S, Bolger AP, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002; 90: 1226-1230.
17. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of TNFα in failing human myocardium after mechanical circulatory support: A potential mechanism of cardiac recovery. Circulation 1999; 100: 1189-1193.
18. Liu PP, Mason JW. Advances in understanding of myocarditis. Circulation 2001; 104: 1076-1082.
19. Staudt A, Schäper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption thrapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-2686.
20. Candy GP, Skudicky D, Mueller UK, et al. Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 740-744.
21. Dorfell Y, Latsch C, Stuhlmuller S, et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117.
22. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
23. 2-adrenergic receptor stimulation regulate CD4 T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001; 53: 487-525.
24. Alaniz RC, Thomas SA, Perez-Melgosa M, et al. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci USA 1999; 96: 2274-2278.
25. Aukrust P, Veland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-382.
26. Luppi P, Rudert WA, Zanone MM, et al. Idiopathic Dilated Cardiomyopathy: A superantigen-driven autoimmune disease Circulation 1998; 98: 777-785.
27. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-1093.
28. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001; 103(8): 1083-1088.